{"filing":{"accession_number":"0001104659-26-066631","cik":"0001638287","ticker":"MTVA","company_name":"MetaVia Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"mtva-20260527x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926066631/mtva-20260527x8k.htm"},"events":[{"id":8670,"run_id":7613,"accession_number":"0001104659-26-066631","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"MetaVia disclosed presentation of Phase 1 clinical data for DA-1726, a novel dual OXM analog agonist, at a major medical conference (EASL 2026). For a biopharmaceutical company, positive clinical trial data presentations at peer-reviewed conferences are material events affecting investor assessment of pipeline progress and commercial prospects. However, the disclosure does not fit neatly into the standard taxonomy categories (not earnings, M\u0026A, litigation, impairment, or other defined event types), warranting classification as other_material.","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1811,"accession_number":"0001104659-26-066631","item_number":"7.01","item_title":"Regulation FD Disclosures.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"MetaVia disclosed presentation of Phase 1 clinical data for DA-1726, a novel dual OXM analog agonist, at a major medical conference (EASL 2026). For a biopharmaceutical company, positive clinical trial data presentations at peer-reviewed conferences are material events affecting investor assessment of pipeline progress and commercial prospects. However, the disclosure does not fit neatly into the standard taxonomy categories (not earnings, M\u0026A, litigation, impairment, or other defined event types), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:09:18.897179+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1811,"accession_number":"0001104659-26-066631","item_number":"7.01","item_title":"Regulation FD Disclosures.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"MetaVia disclosed presentation of Phase 1 clinical data for DA-1726, a novel dual OXM analog agonist, at a major medical conference (EASL 2026). For a biopharmaceutical company, positive clinical trial data presentations at peer-reviewed conferences are material events affecting investor assessment of pipeline progress and commercial prospects. However, the disclosure does not fit neatly into the standard taxonomy categories (not earnings, M\u0026A, litigation, impairment, or other defined event types), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:09:18.897179+00:00","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-05-27"}]}